Background: Allograft coronary artery disease (ACAD) is a common cause of morbidity and mortality post-orthotopic heart transplantation (OHT). ACAD progression may be reduced by modifying cardiovascular risk factors, such as hyperlipidemia and hypertension. We sought to evaluate the management of hyperlipidemia and hypertension among OHT recipients followed in an outpatient cardiac transplant clinic. Objective: The primary objective was to assess the proportion of OHT patients achieving both the recommended LDL target of <2.0 mmol/L and BP targets of <140/90 mmHg (or <130/80 mmHg for diabetics) in an outpatient cardiac transplant clinic. Methods: A cross-sectional retrospective analysis of the medical records of all adult OHT recipients actively followed in our outpatient cardiac transplant between January-March 2009. Results: Of the 193 patients included, both the low-density lipoprotein (LDL) cholesterol and blood pressure (BP) targets were achieved in 111 (57.5%) patients. The LDL target alone was achieved by 140 (72.5%) patients and the BP target alone by 153 (79.3%) patients. Statins were prescribed in 183 (94.8%) patients with a mean LDL of 1.81 mmol/L (±0.55). Angiotensin converting enzyme-inhibitors [ACE-I] (or angiotensin receptor blockers [ARB]) were prescribed in 154 (79.8%) patients, diltiazem in 101 (52.3%) patients, and both in 85 (44.0%) patients, with a mean BP of 124.2/77.8 mmHg (±13.6/8.2). Adverse reactions related to statins, ACE-inhibitors or diltiazem were uncommon and rarely resulted in drug discontinuation. Conclusions: Guideline recommended that LDL and BP targets are achievable in a significant proportion of OHT recipients. The high utilization rates of statins for dyslipidemia and ACE-I (or ARB) and diltiazem for BP were consistent with guideline recommendations for the prevention of ACAD. Despite concerns regarding the potential for pharmacokinetic drug interactions in OHT patients, the reported rates of any drug intolerance to these medications were low in our population.
References
[1]
(2012) E-Statistics Report on Organ Transplants, Waiting Lists and Donor Statistics, 2012 Summary Statistics. Ottawa (ON): Canadian Institute for Health Information. http://www.cihi.ca/CIHI-ext-portal/pdf/internet/REPORT_STATS2012_PDF_EN
[2]
Ross, H., Hendry, P., Dipchand, A., Giannetti, N., Hirsch, G., Isaac, D., et al. (2003) Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. Canadian Journal of Cardiology, 19, 620-654.
[3]
Valantine, H. (2004) Cardiac Allograft Vasculopathy after Heart Transplantation: Risk Factors and Management. Jounal of Heart and Lung Transplantation, 23, S187-S193. http://dx.doi.org/10.1016/j.healun.2004.03.009
[4]
Taylor, D.O., Edwards, L.B., Aurora, P., Christie, J.D., Dobbels, F., Kirk, R., et al. (2008) Registry of the International Society for Heart and Lung Transplantation: Twenty-Fifth Official Adult Heart Transplant Report—2008. Journal of Heart and Lung Transplantation, 27, 943-956. http://dx.doi.org/10.1016/j.healun.2008.06.017
[5]
Wenke, K. (2004) Management of Hyperlipidaemia Associated with Heart Transplantation. Drugs, 64, 1053-1068. http://dx.doi.org/10.2165/00003495-200464100-00003
[6]
Bilchick, K.C., Henrikson, C.A., Skojec, D., Kasper, E.K. and Blumenthal, R.S. (2004) Treatment of Hyperlipidemia in Cardiac Transplant Recipients. American Heart Journal, 148, 200-210. http://dx.doi.org/10.1016/j.ahj.2004.03.050
[7]
Kobashigawa, J.A., Starling, R.C., Mehra, M.R., Kormos, R.L., Bhat, G., Barr, M.L., et al. (2006) Multicenter Retrospective Analysis of Cardiovascular Risk Factors Affecting Long-Term Outcome of de Novo Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 25, 1063-1069. http://dx.doi.org/10.1016/j.healun.2006.05.001
[8]
Mehra, M.R. and Raval, N.Y. (2004) Metaanalysis of Statins and Survival in de Novo Cardiac Transplantation. Transplantation Proceedings, 36, 1539-1541. http://dx.doi.org/10.1016/j.transproceed.2004.05.036
[9]
Kobashigawa, J.A., Katznelson, S., Laks, H., Johnson, J.A., Yeatman, L., Wang, X.M., et al. (1995) Effect of Pravastatin on Outcomes after Cardiac Transplantation. New England Journal of Medicine, 333, 621-627. http://dx.doi.org/10.1056/NEJM199509073331003
[10]
Kobashigawa, J.A., Moriguchi, J.D., Laks, H., Wener, L., Hage, A., Hamilton, M.A., et al. (2005) Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 24, 1736-1740. http://dx.doi.org/10.1016/j.healun.2005.02.009
[11]
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., et al. (1997) Simvastatin Reduces Graft Vessel Disease and Mortality after Heart Transplantation: A Four-Year Randomized Trial. Circulation, 96, 1398-1402. http://dx.doi.org/10.1161/01.CIR.96.5.1398
[12]
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Krobot, K., et al. (2003) Simvastatin Initiated Early after Heart Transplantation: 8-Year Prospective Experience. Circulation, 107, 93-97. http://dx.doi.org/10.1161/01.CIR.0000043241.32523.EE
[13]
Wenke, K., Meiser, B., Thiery, J. and Reichart, B. (2005) Impact of Simvastatin Therapy after Heart Transplantation an 11-Year Prospective Evaluation. Herz, 30, 431-432. http://dx.doi.org/10.1007/s00059-005-2685-6
[14]
Patel, D.N., Pagani, F.D., Koelling, T.M., Dyke, D.B., Baliga, R.R., Cody, R.J., et al. (2002) Safety and Efficacy of Atorvastatin in Heart Transplant Recipients. The Journal of Heart and Lung Transplantation, 21, 204-210. http://dx.doi.org/10.1016/S1053-2498(01)00369-2
[15]
Samman, A., Imai, C., Straatman, L., Frolich, J., Humphries, K. and Ignaszewski, A. (2005) Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients. The Journal of Heart and Lung Transplantation, 24, 1008-1013. http://dx.doi.org/10.1016/j.healun.2004.07.016
[16]
O’Rourke, B., Barbir, M., Mitchell, A.G., Yacoub, M.H. and Banner, N.R. (2004) Efficacy and Safety of Fluvastatin Therapy for Hypercholesterolemia after Heart Transplantation: Results of a Randomised Double Blind Placebo Controlled Study. International Journal of Cardiology, 94, 235-240. http://dx.doi.org/10.1016/j.ijcard.2003.04.009
[17]
Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., et al. (2009) Canadian Cardiovascular Society/Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult—2009 Recommendations. Canadian Journal of Cardiology, 25, 567-579. http://dx.doi.org/10.1016/S0828-282X(09)70715-9
[18]
Page II, R.L., Miller, G.G. and Lindenfeld, J. (2005) Drug Therapy in the Heart Transplant Recipient: Part IV: Drug-Drug Interactions. Circulation, 111, 230-239. http://dx.doi.org/10.1161/01.CIR.0000151805.86933.35
[19]
Patel, A.R., Ambrose, M.S., Duffy, G.A., Cote, H. and DeNofrio, D. (2007) Treatment of Hypercholesterolemia with Ezetimibe in Cardiac Transplant Recipients. The Journal of Heart and Lung Transplantation, 26, 281-284. http://dx.doi.org/10.1016/j.healun.2007.01.008
[20]
Shaw, S.M., Chaggar, P., Ritchie, J., Shah, M.K., Baynes, A.C., O’Neill, N., et al. (2009) The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin. Transplantation, 87, 771-775. http://dx.doi.org/10.1097/TP.0b013e318198d7d0
[21]
Koshman, S.L., Lalonde, L.D., Burton, I., Tymchak, W.J. and Pearson, G.J. (2005) Supratherapeutic Response to Ezetimibe Administered with Cyclosporine. Annals of Pharmacotherapy, 39, 1561-1565. http://dx.doi.org/10.1345/aph.1G015
[22]
Marzoa-Rivas, R., Crespo-Leiro, M.G., Paniagua-Marin, M.J., Llinares-Garcia, D., Muniz-Garcia, J., Aldama-Lopez, G., et al. (2005) Safety of Statins When Response Is Carefully Monitored: A Study of 336 Heart Recipients. Transplantation Proceedings, 37, 4071-4073. http://dx.doi.org/10.1016/j.transproceed.2005.09.163
[23]
Grigioni, F., Carigi, S., Potena, L., Fabbri, F., Russo, A., Musuraca, A.C., et al. (2006) Long-Term Safety and Effectiveness of Statins for Heart Transplant Recipients in Routine Clinical Practice. Transplantation Proceedings, 38, 1507-1510. http://dx.doi.org/10.1016/j.transproceed.2006.02.071
[24]
Brozena, S.C., Johnson, M.R., Ventura, H., Hobbs, R., Miller, L., Olivari, M.T., et al. (1996) Effectiveness and Safety of Diltiazem or Lisinopril in Treatment of Hypertension after Heart Transplantation. Results of a Prospective Randomized Multicenter Trail. Journal of the American College of Cardiology, 27, 1707-1712. http://dx.doi.org/10.1016/0735-1097(96)00057-5
[25]
Rockx, M.A. and Haddad, H. (2007) Use of Calcium Channel Blockers and Angiotensin-Converting Enzyme Inhibitors after Cardiac Transplantation. Current Opinion in Cardiology, 22, 128-132. http://dx.doi.org/10.1097/hco.0b013e3280210681
[26]
Eisen, H.J. (2003) Hypertension in Heart Transplant Recipients: More than Just Cyclosporine. Journal of the American College of Cardiology, 41, 433-434. http://dx.doi.org/10.1016/S0735-1097(02)02821-8
[27]
Erinc, K., Yamani, M.H., Starling, R.C., Crowe, T., Hobbs, R., Bott-Silverman, C., et al. (2005) The Effect of Combined Angiotensin-Converting Enzyme Inhibition and Calcium Antagonism on Allograft Coronary Vasculopathy Validated by Intravascular Ultrasound. The Journal of Heart and Lung Transplantation, 24, 1033-1038. http://dx.doi.org/10.1016/j.healun.2004.06.005
[28]
Mehra, M.R., Ventura, H.O., Smart, F.W., Collins, T.J., Ramee, S.R. and Stapleton, D.D. (1995) An Intravascular Ultrasound Study of the Influence of Angiotensin-Converting Enzyme Inhibitors and Calcium Entry Blockers on the Development of Cardiac Allograft Vasculopathy. American Journal of Cardiology, 75, 853-854. http://dx.doi.org/10.1016/S0002-9149(99)80432-9
[29]
Schroeder, J.S., Gao, S.Z., Alderman, E.L., Hunt, S.A., Johnstone, I., Boothroyd, D.B., et al. (1993) A Preliminary Study of Diltiazem in the Prevention of Coronary Artery Disease in Heart-Transplant Recipients. The New England Journal of Medicine, 328, 164-170. http://dx.doi.org/10.1056/NEJM199301213280303
[30]
Leenen, F.H., Coletta, E. and Davies, R.A. (2007) Prevention of Renal Dysfunction and Hypertension by Amlodipine after Heart Transplant. American Journal of Cardiology, 100, 531-535. http://dx.doi.org/10.1016/j.amjcard.2007.03.058
[31]
Khan, N.A., Hemmelgarn, B., Herman, R.J., Rabkin, S.W., McAlister, F.A., Bell, C.M., et al. (2008) The 2008 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Part 2—Therapy. Canadian Journal of Cardiology, 24, 465-475. http://dx.doi.org/10.1016/S0828-282X(08)70620-2
[32]
de Denus, S., Al-Jazairi, A., Loh, E., Jessup, M., Stanek, E.J. and Spinler, S.A. (2004) Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients. Annals of Pharmacotherapy, 38, 1136-1141. http://dx.doi.org/10.1345/aph.1D535
[33]
Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., et al. (1981) A Method for Estimating the Probability of Adverse Drug Reactions. Clinical Pharmacology & Therapeutics, 30, 239-245. http://dx.doi.org/10.1038/clpt.1981.154
[34]
Yan, A.T., Yan, R.T., Tan, M., Hackam, D.G., Leblanc, K.L., Kertland, H., et al. (2006) Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. American Journal of Medicine, 119, 676-683. http://dx.doi.org/10.1016/j.amjmed.2005.11.015
[35]
Saposnik, G., Goodman, S.G., Leiter, L.A., Yan, R.T., Fitchett, D.H., Bayer, N.H., et al. (2009) Applying the Evidence: Do Patients with Stroke, Coronary Artery Disease, or both Achieve Similar Treatment Goals? Stroke, 40, 1417-1424. http://dx.doi.org/10.1161/STROKEAHA.108.533018
[36]
Pearson, G.J., Stewart, G.G., Burton, I., Chorney, S.G., Tymchak, W.J., Lalonde, L.D. and Burton, J.R. (2004) Successful Treatment to Guideline Recommended LDL Cholesterol Targets in Heart Transplant Recipients. Canadian Journal of Cardiology, 21, 241C.
[37]
Farahani, P. and Levine, M. (2009) Goal Attainment for Multiple Cardiovascular Risk Factors in Community-Based Clinical Practice (a Canadian Experience). Journal of Evaluation in Clinical Practice, 15, 212-216. http://dx.doi.org/10.1111/j.1365-2753.2008.01002.x
